Strategic Momentum: Cache (CACH), Avago Technologies (AVGO), Array BioPharma (ARRY) |
Posted: December 4, 2014 |
Cache Inc. (CACH) Keep a close eye on CACH, which said it has received an inquiry from a third party regarding a potential sale of the Company (no formal or binding offers have been made to date). CACH's Board of Directors has determined to explore and evaluate strategic alternatives including a possible merger, sale or other form of business combination. CACH is a national multi- channel specialty retailer dedicated to dresses, sportswear and accessories designed for special occasions and daily glamour. More about Cache Inc (CACH) at www.cache.com ** Crown Equity Holdings Inc. (CRWE) CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites. One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale. The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada. CRWE has recently included the City of Encinitas, CA ( www.encinitas.crwe-pr.com ) to the CRWE Network. Encinitas is a coastal beach city in San Diego County, California. It is approximately 25 miles north of San Diego in North County and about 95 miles south of Los Angeles. Located along six miles of Pacific Ocean coastline, it was recently named among the 20 best surf towns in the world by National Geographic and many surf contests are held throughout the year in Encinitas. Encinitas had an estimated population in 2013 (U.S. Census Bureau) of approximately 61,588, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday. CRWE plans to have full national coverage of all U.S and Canada businesses in the future on its CRWE-PR Business Directory, which will be integrated to the CRWE Network. The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows CRWE the instant distribution of information to the entire CRWE Network. Online video is gaining strength as a source for content marketing. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com ** Avago Technologies Ltd. (AVGO) AVGO reported strong performance on its financial results For the fourth quarter fiscal 2014, AVGO posted (non-GAAP results from continuing operations) net revenue of $1.61 billion, an increase of 25% sequentially and 118% year over year, and net income of $556 million, or $1.99 per diluted share, versus net income of $347 million, or $1.26 per diluted share in the previous quarter, and net income of $227 million, or $0.89 per diluted share in the same period the prior year. AVGO is a leading designer, developer and global supplier of a broad range of analog semiconductor devices with a focus on III-V based products and complex digital and mixed signal CMOS based devices. More about Avago Technologies Ltd (AVGO) at www.avagotech.com. ** Array BioPharma Inc. (ARRY) ARRY reported that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval. ARRY had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be superseded by a new set of agreements between the parties. Upon deal close, ARRY will receive up to $85 million and Novartis' global, exclusive license to binimetinib will terminate with all rights reverting to ARRY. Novartis has agreed to provide some transitional regulatory, clinical development and manufacturing services, and will assign to ARRY patent and other intellectual property rights it owns to the extent relating to binimetinib. All clinical trials involving binimetinib, including the COLUMBUS, NEMO and MILO pivotal trials, will continue to be conducted as currently contemplated. ARRY is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. More about Array BioPharma Inc. (ARRY) at www.arraybiopharma.com. ** Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
|
||||||||||||||||||||||||||||||||||||||||||
|